Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned ...

Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer ...

Technology moves fast, and there’s no better example than the rapid growth of artificial intelligence (AI). Here at Pfizer, we have long been focused on making breakthroughs that change patients’ ...

Pfizer will publish full proposals of funded initiatives, in addition to any milestone updates, interim reports, final outcomes assessments and any other relevant, pertinent data and information that ...

The Pfizer Futures assessment is designed to help us better understand your potential and identify candidates who may thrive within Pfizer's values-driven culture and future talent pipeline As part of ...

Pfizer Digital continuously seeks opportunities to bring fresh and innovative ideas to our business. The Digital Rotational Program is looking for recent college graduates to join our fast-paced ...

Full-Year 2024 Revenue Guidance (1) Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition Anticipates Approximately $8 Billion in Revenues for Comirnaty (2) and ...

More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies Two late-breaking presentations include longer-term results from ...

Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced ...

More than 45 abstracts, including five late-breaking presentations and recognition in Presidential Symposium, showcase impact of approved medicines and potential of next-generation pipeline NEW YORK-- ...

Financial guidance for Adjusted (2) diluted EPS is calculated using approximately 5.74 billion weighted average shares outstanding, and assumes no share repurchases in 2024 or 2025.

Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig ...